Abstract
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a low-molecular-weight biological response modifier scheduled for clinical evaluation, induced synthesis of tumour necrosis factor-α (TNF-α) in serum of mice, with maximal activity being observed at 2–3 h after administration. At a dose of 27.5 mg/kg, DMXAA induced similar TNF-α concentrations as did flavone-8-acetic acid given at its maximum tolerated dose (MTD; 330 mg/kg), whereas 8-methylxanthenone-4-acetic acid, which has no antitumour activity, did not induce serum TNF-α at its MTD (440 mg/kg). The dependence of schedule on TNF-α induction was studied by giving DMXAA to mice in two doses of 27.5 mg/kg each separated by different intervals. An interval of 0 (i.e 55 mg/kg given in a single dose) produced a TNF-α concentration 9-fold that produced hy a single dose of 27.5 mg/kg. This dose, although higher than the MTD of 30 mg/kg, did not affect the health of mice at the time of assay (3 h). An interval of 1 day produced very low levels of serum TNF-α after the second injection. An interval of 3 days produced high levels of serum TNF-α after the second injection (9-fold that detected in mice receiving 27.5 mg/kg in a single dose) but no long-term toxicity, whereas an interval of 7 days produced an intermediate response. Thus, the first dose can either potentiate or suppress the TNF-α response to a second dose. Mice with advanced subcutaneous colon 38 tumours were treated either with a single dose of DMXAA (27.5 mg/kg) or with a divided dose (two doses of 27.5 mg/kg given 3 days apart). Both the cure rate and the tumour-growth delay were enhanced by the divided-dose schedule. The results are relevant to the design of clinical administration schedules of DMXAA and emphasise the importance of TNF-α induction in the antitumour response.
Similar content being viewed by others
References
Alexander HR, Doherty GM, Block MI, Kragel PJ, Jensen JC, Langstein HN, Walker E, Norton JA (1971) Single-dose tumor necrosis factor protection against endotoxin-induced shock and tissue injury in rats. Infect Immun 59: 3889–3894
Atassi G, Briet P, Berthelon J-J, Collonges F (1985) Synthesis and antitumor activity of some 8-substituted 4-oxo-4H-1-benzopyrans. Eur J Med Chem 5: 393–402
Ching L-M, Baguley BC (1987) Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347512). Eur J Cancer Clin Oncol 23: 1047–1050
Ching L-M, Baguley BC (1988) Enhancement of in vitro toxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512). Eur J Cancer Clin Oncol 24: 1521–1525
Ching L-M, Joseph WR, Zhuang L, Atwell GJ, Rewcastle GR, Denny WA, Baguley BC (1991) Induction of natural killer activity by xanthenone analogues of flavone acetic acid: relation with antitumour activity. Eur J Cancer 27: 79–83
Ching L-M, McKeage M, Joseph WR, Kestell P, Zwi LJ, Baguley BC (1991) Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid. Cancer Chemother Pharmacol 28:414–419
Ching L-M, Finlay GJ, Joseph WR, Baguley BC (1991) In vitro methods for screening agents with an indirect mechanism of antitumour activity: xanthenone analogues of flavone acetic acid. Eur J Cancer 27: 1684–1689
Ching L-M, Joseph WP, Baguley BC (1992) Stimulation of macrophage tumoricidal activity by 5,6-dimethylxanthenone-4-acetic acid, a potent analogue of the antitumor agent flavone-8-acetic acid. Biochem Pharmacol 44: 192–195
Ching LM, Joseph WR, Crosier KE, Baguley BC (1994) Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488) Cancer Res 54: 870–872
Ching L-M, Joseph WR, Zhuang L, Baguley BC (1994) Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours. Cancer Chemother Pharmacol (in press)
Evelhoch JL, Bissery M-C, Chabot GG, Simpson NE, McCoy CL, Heilbrun LK, Corbett TH (1988) Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res 48: 4749–4755
Finlay GJ, Wilson WR, Baguley BC (1986) Comparison of in vitro activity of cytotoxic drugs toward human carcinoma and leukaemia cell lines. Eur J Cancer Clin Oncol 22: 655–662
Futami H, Eader LA, Komschlies KL, Bull R, Gruys ME, Ortaldo JR, Young HA, Wiltrout RH (1991) Flavone acetic acid directly induces expression of cytokine genes in mouse splenic leukocytes but not in human peripheral blood leukocytes. Cancer Res 51: 6596–6602
Futami H, Eader LA, Back TT, Gruys E, Young HA, Wiltrout RH, Baguley BC (1982) Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives. J Immunother 12: 247–255
Haworth C, O'Reilly SM, Chu E, Rustin GJS, Feldmann M (1993) Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III. Cytokine studies. Br J Cancer 67: 1346–1350
Heinzel FP (1990) The role of IFN-gamma in the pathology of experimental endotoxemia. J Immunol 145: 2920–2924
Hogan MM, Vogel SN (1990) Measurement of tumor necrosis factor α and β. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W (eds) Current protocols in immunology, vol 1. Greene Publishing Associates/Wiley Interscience, New York, p 6.10.1
Kerr DJ, Kaye SB (1989) Flavone acetic acid — preclinical and clinical activity. Eur J Cancer Clin Oncol 25: 1271–1272
Mace KF, Hornung RL, Wiltrout RH, Young HA (1990) Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Res 50: 1742–1747
Mahadevan V, Malik STA, Meager A, Fiers W, Lewis GP, Hart IR (1990) Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res 50: 5537–5542
Metcalf D (1991) Control of granulocytes and macrophages — molecular, cellular, and clinical aspects. Science 254: 529–533
Morrisey PJ, Charrier K, Alpert A (1985) In vivo administration of IL-1 induces thymic hypoplasia and increased levels of serum corticosterone. J Immunol 141: 1456–1463
Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxic shock. Nature 348: 550–552
Okamoto T, Watanabe N, Yamauchi N, Tsuji N, Tsuji N, Itoh Y, Neda H, Niitsu Y (1992) Endogenous tumor necrosis factor exerts its protective function intracellularly against the cytotoxicity of exogenous tumor, necrosis factor. Cancer Res 52: 5278–5281
Plowman J, Naryanan VL, Dykes D, Szarvasi E, Briet P, Yoder OC, Paull KD (1986) Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 70: 631–638
Pratesi G, Rodolfo M, Rovetta G, Parmiani G (1990) Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. Eur J Cancer 26: 1079–1083
Rewcastle GW, Atwell GJ, Baguley BC, Calveley SB, Denny WA (1989) Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. J Med Chem 32: 793–799
Rewcastle GW, Kestell P, Baguley BC, Denny WA (1990) Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution. J Natl Cancer Inst 82:528–529
Rewcastle GW, Atwell GJ, Zhuang L, Baguley BC, Denny WA (1991) Potential antitumor agents. 61. Structure-activity relationships forin vivo colon-38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34: 217–222
Selby P, Hobbs, S, Viner C, Jackson E, Jones E, Newell D, Calvert AH, McElwain T, Fearon E, Humphreys J, Shiga T (1987) Tumour necrosis in man: clinical and biological observations. Br J Cancer 56: 803–808
Smith GP, Calveley SB, Smith MJ, Baguley BC (1987) Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol 23: 1209–1212
Thomsen LL, Ching LM, Zhuang L, Gavin JB, Baguley BC (1991) Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 51: 77–81
Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, Zentella A, Albert JD, Shires, GT, Cerami A (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234: 470–474
Wiltrout RH, Boyd MR, Back TC, Salup RR, Arthur JA, Hornung RL (1988) Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. J Immunol 140: 3261–3265
Zwi LJ, Baguley BC, Gavin JB, Wilson WR (1989) Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). J Natl Cancer Inst 81: 1005–1013
Author information
Authors and Affiliations
Additional information
This study was supported by the Auckland Division of the Cancer Society of New Zealand and by the Health Research Council of New Zealand
Rights and permissions
About this article
Cite this article
Philpott, M., Baguley, B.C. & Ching, LM. Induction of tumour necrosis factor-α by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 36, 143–148 (1995). https://doi.org/10.1007/BF00689199
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00689199